Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens.
Pharmacogenet Genomics
; 34(2): 25-32, 2024 Feb 01.
Article
en En
| MEDLINE
| ID: mdl-37910437
ABSTRACT
BACKGROUND:
Excessive weight gain affects some persons with HIV after switching to integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART). We studied associations between CYP2B6 genotype and weight gain after ART switch among ACTG A5001 and A5322 participants.METHODS:
Eligible participants switched from efavirenz- to INSTI-containing ART, had genotype data, and had weight data at least once from 4 weeks to 2 years post-switch. Multivariable linear mixed effects models adjusted for race/ethnicity, CD4, age, BMI and INSTI type assessed relationships between CYP2B6 genotype and estimated differences in weight change.RESULTS:
A total of 159 eligible participants switched ART from 2007 to 2019, of whom 138 had plasma HIV-1 RNAâ <â 200 copies/mL (65 CYP2B6 normal, 56 intermediate, 17 poor metabolizers). Among participants with switch HIV-1 RNAâ <â 200 copies/mL, weight increased in all 3 CYP2B6 groups. The rate of weight gain was greater in CYP2B6 poor than in CYP2B6 normal metabolizers overall, and within 9 subgroups (male, female, White, Black, Hispanic, dolutegravir, elvitegravir, raltegravir, and TDF in the pre-switch regimen); only in Hispanic and elvitegravir subgroups were these associations statistically significant ( P â <â 0.05). Compared to normal metabolizers, CYP2B6 intermediate status was not consistently associated with weight gain.CONCLUSION:
CYP2B6 poor metabolizer genotype was associated with greater weight gain after switch from efavirenz- to INSTI-containing ART, but results were inconsistent. Weight gain in this setting is likely complex and multifactorial.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Inhibidores de Integrasa VIH
/
Fármacos Anti-VIH
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Pharmacogenet Genomics
Asunto de la revista:
FARMACOLOGIA
/
GENETICA MEDICA
Año:
2024
Tipo del documento:
Article